{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T19:25:58Z","timestamp":1780082758423,"version":"3.54.0"},"reference-count":112,"publisher":"Informa UK Limited","issue":"5","license":[{"start":{"date-parts":[[2023,2,23]],"date-time":"2023-02-23T00:00:00Z","timestamp":1677110400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Critical Reviews in Clinical Laboratory Sciences"],"published-print":{"date-parts":[[2023,7,4]]},"DOI":"10.1080\/10408363.2023.2177605","type":"journal-article","created":{"date-parts":[[2023,2,24]],"date-time":"2023-02-24T07:48:59Z","timestamp":1677224939000},"page":"321-345","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":2,"title":["Current status in cellular-based therapies for prevention and treatment of COVID-19"],"prefix":"10.1080","volume":"60","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6956-8743","authenticated-orcid":false,"given":"Dima","family":"Hattab","sequence":"first","affiliation":[{"name":"Faculty of Pharmacy, Al-Ahliyya Amman University, Amman, Jordan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3514-1132","authenticated-orcid":false,"given":"Mumen F. A.","family":"Amer","sequence":"additional","affiliation":[{"name":"Faculty of Pharmacy, Applied Science Private University, Amman, Jordan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4469-1969","authenticated-orcid":false,"given":"Amirah","family":"Mohd Gazzali","sequence":"additional","affiliation":[{"name":"School of Pharmaceutical Sciences, Universiti Sains Malaysia, Penang, Malaysia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8283-0849","authenticated-orcid":false,"given":"Lay Hong","family":"Chuah","sequence":"additional","affiliation":[{"name":"School of Pharmacy, Monash University Malaysia, Selangor, Malaysia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2752-9783","authenticated-orcid":false,"given":"Athirah","family":"Bakhtiar","sequence":"additional","affiliation":[{"name":"School of Pharmacy, Monash University Malaysia, Selangor, Malaysia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2023,2,23]]},"reference":[{"key":"e_1_3_3_2_1","volume-title":"Coronavirus Resource Center [Internet]","year":"2022","unstructured":"Coronavirus Resource Center [Internet]. Baltimore (MD): Johns Hopkins University; 2020-2022 [cited 2022 Nov 2]. Available from: https:\/\/coronavirus.jhu.edu\/map.html"},{"issue":"3","key":"e_1_3_3_3_1","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/j.chom.2020.02.001","article-title":"Genome composition and divergence of the novel coronavirus (2019-nCoV) originating in China","volume":"27","author":"Wu A","year":"2020","unstructured":"Wu A, Peng Y, Huang B, et\u00a0al. Genome composition and divergence of the novel coronavirus (2019-nCoV) originating in China. Cell Host Microbe. 2020;27(3):325\u2013328.","journal-title":"Cell Host Microbe"},{"issue":"9","key":"e_1_3_3_4_1","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1038\/s41401-020-0485-4","article-title":"Structural and functional properties of SARS-CoV-2 spike protein: potential antivirus drug development for COVID-19","volume":"41","author":"Huang Y","year":"2020","unstructured":"Huang Y, Yang C, Xu X-F, et\u00a0al. Structural and functional properties of SARS-CoV-2 spike protein: potential antivirus drug development for COVID-19. Acta Pharmacol Sin. 2020;41(9):1141\u20131149.","journal-title":"Acta Pharmacol Sin"},{"issue":"5","key":"e_1_3_3_5_1","doi-asserted-by":"crossref","first-page":"105951","DOI":"10.1016\/j.ijantimicag.2020.105951","article-title":"Coronavirus disease 2019 (COVID-19): current status and future perspectives","volume":"55","author":"Li H","year":"2020","unstructured":"Li H, Liu SM, Yu XH, et\u00a0al. Coronavirus disease 2019 (COVID-19): current status and future perspectives. Int J Antimicrob Agents. 2020;55(5):105951.","journal-title":"Int J Antimicrob Agents"},{"issue":"10224","key":"e_1_3_3_6_1","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/S0140-6736(20)30251-8","article-title":"Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding","volume":"395","author":"Lu R","year":"2020","unstructured":"Lu R, Zhao X, Li J, et\u00a0al. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet. 2020;395(10224):565\u2013574.","journal-title":"Lancet"},{"key":"e_1_3_3_7_1","volume-title":"Coronavirus (COVID 19) vaccinations- [Internet]","year":"2022","unstructured":"Coronavirus (COVID 19) vaccinations- [Internet]. Oxford: Our World in Data; 2020\u20132022 [cited 2022. Jan 1]. Available from: https:\/\/ourworldindata.org\/covid-vaccinations?country=OWID_WRL"},{"key":"e_1_3_3_8_1","doi-asserted-by":"crossref","first-page":"102779","DOI":"10.1016\/j.jaut.2021.102779","article-title":"Omicron SARS-CoV-2 variant: unique features and their impact on pre-existing antibodies","volume":"126","author":"Kannan SR","year":"2022","unstructured":"Kannan SR, Spratt AN, Sharma K, et\u00a0al. Omicron SARS-CoV-2 variant: unique features and their impact on pre-existing antibodies. J Autoimmun. 2022;126:102779.","journal-title":"J Autoimmun"},{"issue":"1","key":"e_1_3_3_9_1","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/nrd.2018.168","article-title":"Drug repurposing: progress, challenges, and recommendations","volume":"18","author":"Pushpakom S","year":"2019","unstructured":"Pushpakom S, Iorio F, Eyers PA, et\u00a0al. Drug repurposing: progress, challenges, and recommendations. Nat Rev Drug Discov. 2019;18(1):41\u201358. \u200f","journal-title":"Nat Rev Drug Discov"},{"issue":"9","key":"e_1_3_3_10_1","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1016\/j.jcyt.2020.04.100","article-title":"Emerging trends in COVID-19 treatment: learning from inflammatory conditions associated with cellular therapies","volume":"22","author":"Cancio M","year":"2020","unstructured":"Cancio M, Ciccocioppo R, Rocco P, et\u00a0al. Emerging trends in COVID-19 treatment: learning from inflammatory conditions associated with cellular therapies. Cytotherapy. 2020;22(9):474\u2013481.","journal-title":"Cytotherapy"},{"issue":"1","key":"e_1_3_3_11_1","first-page":"1","article-title":"Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoV","volume":"11","author":"Ou X","year":"2020","unstructured":"Ou X, Liu Y, Lei X, et\u00a0al. Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoV. Nat Commun. 2020;11(1):1\u201312. \u200f","journal-title":"Nat Commun"},{"issue":"9","key":"e_1_3_3_12_1","doi-asserted-by":"crossref","first-page":"e202000786","DOI":"10.26508\/lsa.202000786","article-title":"TMPRSS2 and furin are both essential for proteolytic activation of SARS-CoV-2 in human airway cells","volume":"3","author":"Bestle D","year":"2020","unstructured":"Bestle D, Heindl MR, Limburg H, et\u00a0al. TMPRSS2 and furin are both essential for proteolytic activation of SARS-CoV-2 in human airway cells. Life Sci Alliance. 2020;3(9):e202000786.","journal-title":"Life Sci Alliance"},{"issue":"10","key":"e_1_3_3_13_1","doi-asserted-by":"crossref","first-page":"e105114","DOI":"10.15252\/embj.20105114","article-title":"SARS-CoV-2 receptor ACE2 and TMPRSS2 are primarily expressed in bronchial transient secretory cells","volume":"39","author":"Lukassen S","year":"2020","unstructured":"Lukassen S, Chua RL, Trefzer T, et\u00a0al. SARS-CoV-2 receptor ACE2 and TMPRSS2 are primarily expressed in bronchial transient secretory cells. EMBO J. 2020;39(10):e105114.","journal-title":"EMBO J"},{"issue":"5","key":"e_1_3_3_14_1","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1016\/j.cell.2020.04.026","article-title":"Imbalanced host response to SARS-CoV-2 drives development of COVID-19","volume":"181","author":"Blanco-Melo D","year":"2020","unstructured":"Blanco-Melo D, Nilsson-Payant BE, Liu WC, et\u00a0al. Imbalanced host response to SARS-CoV-2 drives development of COVID-19. Cell. 2020;181(5):1036\u20131045.e9.","journal-title":"Cell"},{"issue":"1","key":"e_1_3_3_15_1","doi-asserted-by":"crossref","first-page":"e20190295","DOI":"10.1084\/jem.20190295","article-title":"Type III interferons: balancing tissue tolerance and resistance to pathogen invasion","volume":"217","author":"Broggi A","year":"2020","unstructured":"Broggi A, Granucci F, Zanoni I. Type III interferons: balancing tissue tolerance and resistance to pathogen invasion. J Exp Med. 2020;217(1):e20190295.","journal-title":"J Exp Med"},{"issue":"6504","key":"e_1_3_3_16_1","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1126\/science.abc3545","article-title":"Type III interferons disrupt the lung epithelial barrier upon viral recognition","volume":"369","author":"Broggi A","year":"2020","unstructured":"Broggi A, Ghosh S, Sposito B, et\u00a0al. Type III interferons disrupt the lung epithelial barrier upon viral recognition. Science. 2020;369(6504):706\u2013712.","journal-title":"Science"},{"key":"e_1_3_3_17_1","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1146\/annurev-micro-020518-115759","article-title":"Human coronavirus: host-pathogen interaction","volume":"73","author":"Fung TS","year":"2019","unstructured":"Fung TS, Liu DX. Human coronavirus: host-pathogen interaction. Annu Rev Microbiol. 2019;73:529\u2013557.","journal-title":"Annu Rev Microbiol"},{"issue":"1","key":"e_1_3_3_18_1","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/s12929-022-00793-3","article-title":"Early innate immune response triggered by the human respiratory syncytial virus and its regulation by ubiquitination\/deubiquitination processes","volume":"29","author":"Mart\u00edn-Vicente M","year":"2022","unstructured":"Mart\u00edn-Vicente M, Resino S, Mart\u00ednez I. Early innate immune response triggered by the human respiratory syncytial virus and its regulation by ubiquitination\/deubiquitination processes. J Biomed Sci. 2022;29(1):11.","journal-title":"J Biomed Sci"},{"key":"e_1_3_3_19_1","doi-asserted-by":"crossref","first-page":"1708","DOI":"10.3389\/fimmu.2020.01708","article-title":"Cytokine storm in COVID-19: the current evidence and treatment strategies","volume":"11","author":"Tang Y","year":"2020","unstructured":"Tang Y, Liu J, Zhang D, et\u00a0al. Cytokine storm in COVID-19: the current evidence and treatment strategies. Front Immunol. 2020;11:1708.","journal-title":"Front Immunol"},{"issue":"6","key":"e_1_3_3_20_1","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1038\/s41577-020-0311-8","article-title":"The trinity of COVID-19: immunity, inflammation and intervention","volume":"20","author":"\u200fTay MZ","year":"2020","unstructured":"\u200fTay MZ, Poh CM, R\u00e9nia L, et\u00a0al. The trinity of COVID-19: immunity, inflammation and intervention. Nat Rev Immunol. 2020;20(6):363\u2013374.","journal-title":"Nat Rev Immunol"},{"key":"e_1_3_3_21_1","volume-title":"Coronavirus disease 2019 (COVID-19) treatment guidelines [Internet]","year":"2021","unstructured":"Coronavirus disease 2019 (COVID-19) treatment guidelines [Internet]. Windsor Mill (MD): US Department of Health and Human Services; [cited 2021 Nov 13]. Available from: https:\/\/www.covid19treatmentguidelines.nih.gov\/"},{"issue":"1","key":"e_1_3_3_22_1","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1038\/s41591-021-01643-9","article-title":"A guide to immunotherapy for COVID-19","volume":"28","author":"van de Veerdonk FL","year":"2022","unstructured":"van de Veerdonk FL, Giamarellos-Bourboulis E, Pickkers P, et\u00a0al. A guide to immunotherapy for COVID-19. Nat Med. 2022;28(1):39\u201350.","journal-title":"Nat Med"},{"issue":"19","key":"e_1_3_3_23_1","doi-asserted-by":"crossref","first-page":"4953","DOI":"10.1016\/j.cell.2021.08.016","article-title":"The interferon landscape along the respiratory tract impacts the severity of COVID-19","volume":"184","author":"Sposito B","year":"2021","unstructured":"Sposito B, Broggi A, Pandolfi L, et\u00a0al. The interferon landscape along the respiratory tract impacts the severity of COVID-19. Cell. 2021;184(19):4953\u20134968.e16.","journal-title":"Cell"},{"issue":"3","key":"e_1_3_3_24_1","doi-asserted-by":"crossref","first-page":"e00103\u2013e00120","DOI":"10.1128\/CMR.00103-20","article-title":"Viral respiratory pathogens and lung injury","volume":"34","author":"Clementi N","year":"2021","unstructured":"Clementi N, Ghosh S, De Santis M, et\u00a0al. Viral respiratory pathogens and lung injury. Clin Microbiol Rev. 2021;34(3):e00103\u2013e00120.","journal-title":"Clin Microbiol Rev"},{"issue":"1","key":"e_1_3_3_25_1","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1111\/all.15004","article-title":"A bird\u2019s eye view on the role of dendritic cells in SARS-CoV-2 infection: perspectives for immune-based vaccines","volume":"77","author":"Galati D","year":"2022","unstructured":"Galati D, Zanotta S, Capitelli L, et\u00a0al. A bird\u2019s eye view on the role of dendritic cells in SARS-CoV-2 infection: perspectives for immune-based vaccines. Allergy. 2022;77(1):100\u2013110.","journal-title":"Allergy"},{"issue":"1","key":"e_1_3_3_26_1","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/imm.12888","article-title":"Human dendritic cell subsets: an update","volume":"154","author":"Collin M","year":"2018","unstructured":"Collin M, Bigley V. Human dendritic cell subsets: an update. Immunology. 2018;154(1):3\u201320.","journal-title":"Immunology"},{"key":"e_1_3_3_27_1","doi-asserted-by":"crossref","first-page":"101303","DOI":"10.1016\/j.smim.2019.101303","article-title":"Type III IFNs: beyond antiviral protection","volume":"43","author":"Kotenko SV","year":"2019","unstructured":"Kotenko SV, Rivera A, Parker D, et\u00a0al. Type III IFNs: beyond antiviral protection. Semin Immunol. 2019;43:101303.","journal-title":"Semin Immunol"},{"issue":"3","key":"e_1_3_3_28_1","doi-asserted-by":"crossref","first-page":"653","DOI":"10.4049\/jimmunol.1800218","article-title":"Classical type 1 dendritic cells dominate priming of Th1 responses to herpes simplex virus type 1 skin infection","volume":"202","author":"Harpur CM","year":"2019","unstructured":"Harpur CM, Kato Y, Dewi ST, et\u00a0al. Classical type 1 dendritic cells dominate priming of Th1 responses to herpes simplex virus type 1 skin infection. J Immunol. 2019;202(3):653\u2013663.","journal-title":"J Immunol"},{"issue":"21","key":"e_1_3_3_29_1","doi-asserted-by":"crossref","first-page":"12090","DOI":"10.1128\/JVI.78.21.12090-12095.2004","article-title":"DC-SIGN and DC-SIGNR interact with the glycoprotein of Marburg virus and the S protein of severe acute respiratory syndrome coronavirus","volume":"78","author":"Marzi A","year":"2004","unstructured":"Marzi A, Gramberg T, Simmons G, et\u00a0al. DC-SIGN and DC-SIGNR interact with the glycoprotein of Marburg virus and the S protein of severe acute respiratory syndrome coronavirus. J Virol. 2004;78(21):12090\u201312095.","journal-title":"J Virol"},{"issue":"2","key":"e_1_3_3_30_1","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.cell.2020.02.058","article-title":"Structure, function, and antigenicity of the SARS-CoV- Spike glycoprotein","volume":"181","author":"Walls AC","year":"2020","unstructured":"Walls AC, Park YJ, Tortorici MA, et\u00a0al. Structure, function, and antigenicity of the SARS-CoV- Spike glycoprotein. Cell. 2020;181(2):281\u2013292.e6.","journal-title":"Cell"},{"issue":"6","key":"e_1_3_3_31_1","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1016\/j.celrep.2017.10.054","article-title":"An IRF-3-, IRF-5-, and IRF-7-independent pathway of dengue viral resistance utilizes IRF-1 to stimulate type I and II interferon responses","volume":"21","author":"Carlin AF","year":"2017","unstructured":"Carlin AF, Plummer EM, Vizcarra EA, et\u00a0al. An IRF-3-, IRF-5-, and IRF-7-independent pathway of dengue viral resistance utilizes IRF-1 to stimulate type I and II interferon responses. Cell Rep. 2017;21(6):1600\u20131612.","journal-title":"Cell Rep"},{"issue":"4","key":"e_1_3_3_32_1","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1016\/S2213-2600(20)30076-X","article-title":"Pathological findings of COVID-19 associated with acute respiratory distress syndrome","volume":"8","author":"Xu Z","year":"2020","unstructured":"Xu Z, Shi L, Wang Y, et\u00a0al. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Lancet Respir Med. 2020;8(4):420\u2013422.","journal-title":"Lancet Respir Med"},{"issue":"7","key":"e_1_3_3_33_1","doi-asserted-by":"crossref","first-page":"2366","DOI":"10.1182\/blood-2004-10-4166","article-title":"Chemokine up-regulation in SARS-coronavirus-infected, monocyte-derived human dendritic cells","volume":"106","author":"Law HKW","year":"2005","unstructured":"Law HKW, Cheung CY, Ng HY, et\u00a0al. Chemokine up-regulation in SARS-coronavirus-infected, monocyte-derived human dendritic cells. Blood. 2005;106(7):2366\u20132374.","journal-title":"Blood"},{"key":"e_1_3_3_34_1","first-page":"454\u2013455","article-title":"Productive replication of Middle East respiratory syndrome coronavirus in monocyte-derived dendritic cells modulates innate immune response","author":"Chu H","year":"2014","unstructured":"Chu H, Zhou J, Wong BH, et\u00a0al. Productive replication of Middle East respiratory syndrome coronavirus in monocyte-derived dendritic cells modulates innate immune response. Virology. 2014;:454\u2013455:197\u2013205.","journal-title":"Virology"},{"issue":"2","key":"e_1_3_3_35_1","doi-asserted-by":"crossref","first-page":"406","DOI":"10.7150\/ijms.47706","article-title":"DCs-based therapies: potential strategies in severe SARS-CoV-2 infection","volume":"18","author":"Han J","year":"2021","unstructured":"Han J, Sun J, Zhang G, et\u00a0al. DCs-based therapies: potential strategies in severe SARS-CoV-2 infection. Int J Med Sci. 2021;18(2):406\u2013418.","journal-title":"Int J Med Sci"},{"issue":"5","key":"e_1_3_3_36_1","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1093\/infdis\/jiaa356","article-title":"Attenuated interferon and proinflammatory response in SARS-CoV-2-Infected human dendritic cells is associated with viral antagonism of STAT1 phosphorylation","volume":"222","author":"Yang D","year":"2020","unstructured":"Yang D, Chu H, Hou Y, et\u00a0al. Attenuated interferon and proinflammatory response in SARS-CoV-2-Infected human dendritic cells is associated with viral antagonism of STAT1 phosphorylation. J Infect Dis. 2020;222(5):734\u2013745.","journal-title":"J Infect Dis"},{"issue":"4","key":"e_1_3_3_37_1","doi-asserted-by":"crossref","first-page":"864.e5","DOI":"10.1016\/j.immuni.2020.07.026","article-title":"Acute SARS-CoV-2 infection impairs dendritic cell and T cell responses","volume":"53","author":"Zhou R","year":"2020","unstructured":"Zhou R, To KK, Wong YC, et\u00a0al. Acute SARS-CoV-2 infection impairs dendritic cell and T cell responses. Immunity. 2020;53(4):864.e5\u2013877.e5.","journal-title":"Immunity"},{"key":"e_1_3_3_38_1","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.3389\/fimmu.2018.01869","article-title":"Natural killer cells: development, maturation, and clinical utilization","volume":"9","author":"Abel AM","year":"2018","unstructured":"Abel AM, Yang C, Thakar MS, et\u00a0al. Natural killer cells: development, maturation, and clinical utilization. Front Immunol. 2018;9:1869.","journal-title":"Front Immunol"},{"issue":"8","key":"e_1_3_3_39_1","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1177\/1753425918800200","article-title":"When and how NK cell-induced programmed cell death benefits immunological protection against intracellular pathogen infection","volume":"24","author":"Beliz\u00e1rio JE","year":"2018","unstructured":"Beliz\u00e1rio JE, Neyra JM, Set\u00fabal Destro Rodrigues MF. When and how NK cell-induced programmed cell death benefits immunological protection against intracellular pathogen infection. Innate Immun. 2018;24(8):452\u2013465.","journal-title":"Innate Immun"},{"issue":"7","key":"e_1_3_3_40_1","first-page":"235","article-title":"Natural regulators\u201d: NK cells as modulators of T cell immunity","volume":"14","author":"Schuster IS","year":"2016","unstructured":"Schuster IS, Coudert JD, Andoniou CE, et\u00a0al. \u201cNatural regulators\u201d: NK cells as modulators of T cell immunity. Front Immunol. 2016;14(7):235.","journal-title":"Front Immunol"},{"issue":"1","key":"e_1_3_3_41_1","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1038\/cdd.2013.26","article-title":"Molecular mechanisms of natural killer cell activation in response to cellular stress","volume":"21","author":"Chan CJ","year":"2014","unstructured":"Chan CJ, Smyth MJ, Martinet L. Molecular mechanisms of natural killer cell activation in response to cellular stress. Cell Death Differ. 2014;21(1):5\u201314.","journal-title":"Cell Death Differ"},{"issue":"6","key":"e_1_3_3_42_1","doi-asserted-by":"crossref","first-page":"992.e3","DOI":"10.1016\/j.chom.2020.04.009","article-title":"Complex immune dysregulation in COVID-19 patients with severe respiratory failure","volume":"27","author":"Giamarellos-Bourboulis EJ","year":"2020","unstructured":"Giamarellos-Bourboulis EJ, Netea MG, Rovina N, et\u00a0al. Complex immune dysregulation in COVID-19 patients with severe respiratory failure. Cell Host Microbe. 2020;27(6):992.e3\u20131000.e3.","journal-title":"Cell Host Microbe"},{"key":"e_1_3_3_43_1","doi-asserted-by":"crossref","first-page":"827","DOI":"10.3389\/fimmu.2020.00827","article-title":"Reduction and functional exhaustion of T cells in patients with coronavirus disease 2019 (COVID-19)","volume":"11","author":"Diao B","year":"2020","unstructured":"Diao B, Wang C, Tan Y, et\u00a0al. Reduction and functional exhaustion of T cells in patients with coronavirus disease 2019 (COVID-19). Front Immunol. 2020;11:827.","journal-title":"Front Immunol"},{"issue":"5","key":"e_1_3_3_44_1","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1038\/s41423-020-0402-2","article-title":"Functional exhaustion of antiviral lymphocytes in COVID-19 patients","volume":"17","author":"Zheng M","year":"2020","unstructured":"Zheng M, Gao Y, Wang G, et\u00a0al. Functional exhaustion of antiviral lymphocytes in COVID-19 patients. Cell Mol Immunol. 2020;17(5):533\u2013535.","journal-title":"Cell Mol Immunol"},{"issue":"7","key":"e_1_3_3_45_1","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1038\/s41591-020-0944-y","article-title":"A single-cell atlas of the peripheral immune response in patients with severe COVID-19","volume":"26","author":"Wilk AJ","year":"2020","unstructured":"Wilk AJ, Rustagi A, Zhao NQ, et\u00a0al. A single-cell atlas of the peripheral immune response in patients with severe COVID-19. Nat Med. 2020;26(7):1070\u20131076.","journal-title":"Nat Med"},{"issue":"10","key":"e_1_3_3_46_1","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1002\/jmv.25819","article-title":"Neutrophil-to-lymphocyte ratio and lymphocyte-to-C-reactive protein ratio in patients with severe coronavirus disease 2019 (COVID-19): a meta-analysis","volume":"92","author":"Lagunas-Rangel FA.","year":"2020","unstructured":"Lagunas-Rangel FA. Neutrophil-to-lymphocyte ratio and lymphocyte-to-C-reactive protein ratio in patients with severe coronavirus disease 2019 (COVID-19): a meta-analysis. J Med Virol. 2020;92(10):1733\u20131734.","journal-title":"J Med Virol"},{"key":"e_1_3_3_47_1","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.cytogfr.2020.06.001","article-title":"SARS-CoV-2 infection: the role of cytokines in COVID-19 disease","volume":"54","author":"Costela-Ruiz VJ","year":"2020","unstructured":"Costela-Ruiz VJ, Illescas-Montes R, Puerta-Puerta JM, et\u00a0al. SARS-CoV-2 infection: the role of cytokines in COVID-19 disease. Cytokine Growth Factor Rev. 2020;54:62\u201375.","journal-title":"Cytokine Growth Factor Rev"},{"issue":"7833","key":"e_1_3_3_48_1","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1038\/s41586-020-2598-9","article-title":"SARS-CoV-2-reactive T cells in healthy donors and patients with COVID-19","volume":"587","author":"Braun J","year":"2020","unstructured":"Braun J, Loyal L, Frentsch M, et\u00a0al. SARS-CoV-2-reactive T cells in healthy donors and patients with COVID-19. Nature. 2020;587(7833):270\u2013274.","journal-title":"Nature"},{"issue":"9","key":"e_1_3_3_49_1","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1038\/s41577-020-0402-6","article-title":"E. T cell responses in patients with COVID-19","volume":"20","author":"Chen Z","year":"2020","unstructured":"Chen Z, Wherry J. E. T cell responses in patients with COVID-19. Nat Rev Immunol. 2020;20(9):529\u2013536.","journal-title":"Nat Rev Immunol"},{"issue":"3","key":"e_1_3_3_50_1","doi-asserted-by":"crossref","first-page":"219","DOI":"10.6026\/97320630016219","article-title":"CoViD-19 immunopathology and immunotherapy","volume":"16","author":"Chiappelli F","year":"2020","unstructured":"Chiappelli F, Khakshooy A, Greenberg G. CoViD-19 immunopathology and immunotherapy. Bioinformation. 2020;16(3):219\u2013222.","journal-title":"Bioinformation"},{"issue":"5","key":"e_1_3_3_51_1","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1038\/s41423-020-0401-3","article-title":"Elevated exhaustion levels and reduced functional diversity of T cells in peripheral blood may predict severe progression in COVID-19 patients","volume":"17","author":"Zheng HY","year":"2020","unstructured":"Zheng HY, Zhang M, Yang CX, et\u00a0al. Elevated exhaustion levels and reduced functional diversity of T cells in peripheral blood may predict severe progression in COVID-19 patients. Cell Mol Immunol. 2020;17(5):541\u2013543. \u200f","journal-title":"Cell Mol Immunol"},{"issue":"48","key":"e_1_3_3_52_1","doi-asserted-by":"crossref","first-page":"eabd2071","DOI":"10.1126\/sciimmunol.abd2071","article-title":"Phenotype and kinetics of SARS-CoV-2-specific T cells in COVID-19 patients with acute respiratory distress syndrome","volume":"5","author":"Weiskopf D","year":"2020","unstructured":"Weiskopf D, Schmitz KS, Raadsen MP, et\u00a0al. Phenotype and kinetics of SARS-CoV-2-specific T cells in COVID-19 patients with acute respiratory distress syndrome. Sci Immunol. 2020;5(48):eabd2071. \u200f","journal-title":"Sci Immunol"},{"issue":"3","key":"e_1_3_3_53_1","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1111\/imm.13223","article-title":"Immunopathological characteristics of coronavirus disease 2019 cases in Guangzhou, China","volume":"160","author":"Tan M","year":"2020","unstructured":"Tan M, Liu Y, Zhou R, et\u00a0al. Immunopathological characteristics of coronavirus disease 2019 cases in Guangzhou, China. Immunology. 2020;160(3):261\u2013268.","journal-title":"Immunology"},{"key":"e_1_3_3_54_1","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/s40560-020-00453-4","article-title":"Lymphopenia in severe coronavirus disease-2019 (COVID-19): systematic review and meta-analysis","volume":"8","author":"Huang I","year":"2020","unstructured":"Huang I, Pranata R. Lymphopenia in severe coronavirus disease-2019 (COVID-19): systematic review and meta-analysis. J Intensive Care. 2020;8:36.","journal-title":"J Intensive Care"},{"issue":"8","key":"e_1_3_3_55_1","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1038\/s41587-020-0602-4","article-title":"COVID-19 severity correlates with airway epithelium-immune cell interactions identified by single-cell analysis","volume":"38","author":"Chua RL","year":"2020","unstructured":"Chua RL, Lukassen S, Trump S, et\u00a0al. COVID-19 severity correlates with airway epithelium-immune cell interactions identified by single-cell analysis. Nat Biotechnol. 2020;38(8):970\u2013979.","journal-title":"Nat Biotechnol"},{"issue":"5","key":"e_1_3_3_56_1","doi-asserted-by":"crossref","first-page":"151041","DOI":"10.1016\/j.ejcb.2019.04.002","article-title":"Mesenchymal stem cell therapy for the treatment of inflammatory diseases: challenges, opportunities, and future perspectives","volume":"98","author":"Regmi S","year":"2019","unstructured":"Regmi S, Pathak S, Kim JO, et\u00a0al. Mesenchymal stem cell therapy for the treatment of inflammatory diseases: challenges, opportunities, and future perspectives. Eur J Cell Biol. 2019;98(5-8):151041.","journal-title":"Eur J Cell Biol"},{"key":"e_1_3_3_57_1","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.jconrel.2020.06.036","article-title":"Mesenchymal stromal cells and their secreted extracellular vesicles as therapeutic tools for COVID-19 pneumonia?","volume":"325","author":"Muraca M","year":"2020","unstructured":"Muraca M, Pessina A, Pozzobon M, et\u00a0al. Mesenchymal stromal cells and their secreted extracellular vesicles as therapeutic tools for COVID-19 pneumonia? J Control Release. 2020;325:135\u2013140.","journal-title":"J Control Release"},{"issue":"2","key":"e_1_3_3_58_1","doi-asserted-by":"crossref","first-page":"216","DOI":"10.14336\/AD.2020.0228","article-title":"Transplantation of ACE2-mesenchymal stem cells improves the outcome of patients with COVID-19 pneumonia","volume":"11","author":"Leng Z","year":"2020","unstructured":"Leng Z, Zhu R, Hou W, et\u00a0al. Transplantation of ACE2-mesenchymal stem cells improves the outcome of patients with COVID-19 pneumonia. Aging Dis. 2020;11(2):216\u2013228.","journal-title":"Aging Dis"},{"key":"e_1_3_3_59_1","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1186\/s13287-021-02502-7","article-title":"Is there a place for mesenchymal stromal cell-based therapies in the therapeutic armamentarium against COVID-19?","volume":"12","author":"da Silva KN","year":"2021","unstructured":"da Silva KN, Gobatto ALN, Costa-Ferro \u2009, et\u00a0al. Is there a place for mesenchymal stromal cell-based therapies in the therapeutic armamentarium against COVID-19? Stem Cell Res Ther. 2021;12:425.","journal-title":"Stem Cell Res Ther"},{"issue":"1","key":"e_1_3_3_60_1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13287-020-1550-0","article-title":"Exosomes derived from human umbilical cord mesenchymal stem cells ameliorate IL-6-induced acute liver injury through miR-455-3p","volume":"11","author":"Shao M","year":"2020","unstructured":"Shao M, Xu Q, Wu Z, et\u00a0al. Exosomes derived from human umbilical cord mesenchymal stem cells ameliorate IL-6-induced acute liver injury through miR-455-3p. Stem Cell Res Ther. 2020;11(1):1\u201313.","journal-title":"Stem Cell Res Ther"},{"issue":"11","key":"e_1_3_3_61_1","first-page":"2012","article-title":"Intravenous transplantation of mesenchymal stem cells attenuates oleic acid induced acute lung injury in rats","volume":"125","author":"Xu YL","year":"2012","unstructured":"Xu YL, Liu YL, Wang Q, et\u00a0al. Intravenous transplantation of mesenchymal stem cells attenuates oleic acid induced acute lung injury in rats. Chin Med J. 2012;125(11):2012\u20132018.","journal-title":"Chin Med J"},{"issue":"9","key":"e_1_3_3_62_1","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.7150\/ijbs.4989","article-title":"IL-6 trans-signaling via the soluble IL-6 receptor: importance for the pro-inflammatory activities of IL-6","volume":"8","author":"Rose-John S.","year":"2012","unstructured":"Rose-John S. IL-6 trans-signaling via the soluble IL-6 receptor: importance for the pro-inflammatory activities of IL-6. Int J Biol Sci. 2012;8(9):1237\u20131247.","journal-title":"Int J Biol Sci"},{"issue":"1","key":"e_1_3_3_63_1","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1186\/s13287-020-01612-y","article-title":"Mesenchymal stem cells regulate the Th17\/Treg cell balance partly through hepatocyte growth factor in\u00a0vitro","volume":"11","author":"Chen QH","year":"2020","unstructured":"Chen QH, Wu F, Liu L, et\u00a0al. Mesenchymal stem cells regulate the Th17\/Treg cell balance partly through hepatocyte growth factor in\u00a0vitro. Stem Cell Res Ther. 2020;11(1):91.","journal-title":"Stem Cell Res Ther"},{"issue":"1","key":"e_1_3_3_64_1","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1182\/blood-2005-07-2657","article-title":"Human mesenchymal stem cells modulate B-cell functions","volume":"107","author":"Corcione A","year":"2006","unstructured":"Corcione A, Benvenuto F, Ferretti E, et\u00a0al. Human mesenchymal stem cells modulate B-cell functions. Blood. 2006;107(1):367\u2013372.","journal-title":"Blood"},{"issue":"1","key":"e_1_3_3_65_1","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1186\/s13287-019-1488-2","article-title":"Mesenchymal stem cells induce dendritic cell immune tolerance via paracrine hepatocyte growth factor to alleviate acute lung injury","volume":"10","author":"Lu Z","year":"2019","unstructured":"Lu Z, Chang W, Meng S, et\u00a0al. Mesenchymal stem cells induce dendritic cell immune tolerance via paracrine hepatocyte growth factor to alleviate acute lung injury. Stem Cell Res Ther. 2019;10(1):372.","journal-title":"Stem Cell Res Ther"},{"issue":"3","key":"e_1_3_3_66_1","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.4049\/jimmunol.1102996","article-title":"Mesenchymal stem\/stromal cells induce the generation of novel IL-10-dependent regulatory dendritic cells by SOCS3 activation","volume":"189","author":"Liu X","year":"2012","unstructured":"Liu X, Qu X, Chen Y, et\u00a0al. Mesenchymal stem\/stromal cells induce the generation of novel IL-10-dependent regulatory dendritic cells by SOCS3 activation. J Immunol. 2012;189(3):1182\u20131192.","journal-title":"J Immunol"},{"key":"e_1_3_3_67_1","doi-asserted-by":"crossref","first-page":"2347938","DOI":"10.1155\/2016\/2347938","article-title":"The vascular endothelial growth factors-expressing character of mesenchymal stem cells plays a positive role in treatment of acute lung injury in\u00a0vivo","volume":"2016","author":"Yang Y","year":"2016","unstructured":"Yang Y, Hu S, Xu X, et\u00a0al. The vascular endothelial growth factors-expressing character of mesenchymal stem cells plays a positive role in treatment of acute lung injury in\u00a0vivo. Mediators Inflamm. 2016;2016:2347938.","journal-title":"Mediators Inflamm"},{"issue":"10","key":"e_1_3_3_68_1","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.5966\/sctm.2015-0337","article-title":"Hepatocyte growth factor is required for mesenchymal stromal cell protection against bleomycin-Induced pulmonary fibrosis","volume":"5","author":"Cahill EF","year":"2016","unstructured":"Cahill EF, Kennelly H, Carty F, et\u00a0al. Hepatocyte growth factor is required for mesenchymal stromal cell protection against bleomycin-Induced pulmonary fibrosis. Stem Cells Transl Med. 2016;5(10):1307\u20131318.","journal-title":"Stem Cells Transl Med"},{"key":"e_1_3_3_69_1","doi-asserted-by":"crossref","first-page":"339","DOI":"10.3389\/fimmu.2017.00339","article-title":"Antimicrobial activity of mesenchymal stem cells: current status and new perspectives of antimicrobial peptide-based therapies","volume":"8","author":"Alcayaga-Miranda F","year":"2017","unstructured":"Alcayaga-Miranda F, Cuenca J, Khoury M. Antimicrobial activity of mesenchymal stem cells: current status and new perspectives of antimicrobial peptide-based therapies. Front Immunol. 2017;8:339.","journal-title":"Front Immunol"},{"key":"e_1_3_3_70_1","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.tube.2016.09.005","article-title":"BCG infection in mice is promoted by na\u00efve mesenchymal stromal cells (MSC) and suppressed by poly(A: u)-conditioned MSC","volume":"101","author":"Schwartz YS","year":"2016","unstructured":"Schwartz YS, Belogorodtsev SN, Filimonov PN, et\u00a0al. BCG infection in mice is promoted by na\u00efve mesenchymal stromal cells (MSC) and suppressed by poly(A: u)-conditioned MSC. Tuberculosis. 2016;101:130\u2013136.","journal-title":"Tuberculosis"},{"key":"e_1_3_3_71_1","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1186\/s12865-014-0041-4","article-title":"Leukemia inhibitory factor protects the lung during respiratory syncytial viral infection","volume":"15","author":"Foronjy RF","year":"2014","unstructured":"Foronjy RF, Dabo AJ, Cummins N, et\u00a0al. Leukemia inhibitory factor protects the lung during respiratory syncytial viral infection. BMC Immunol. 2014;15:41.","journal-title":"BMC Immunol"},{"key":"e_1_3_3_72_1","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.bbi.2014.11.010","article-title":"Leukemia inhibitory factor tips the immune balance towards regulatory T cells in multiple sclerosis","volume":"45","author":"Janssens K","year":"2015","unstructured":"Janssens K, Van den Haute C, Baekelandt V, et\u00a0al. Leukemia inhibitory factor tips the immune balance towards regulatory T cells in multiple sclerosis. Brain Behav Immun. 2015;45:180\u2013188.","journal-title":"Brain Behav Immun"},{"key":"e_1_3_3_73_1","doi-asserted-by":"crossref","first-page":"118102","DOI":"10.1016\/j.lfs.2020.118102","article-title":"Contribution of monocytes and macrophages to the local tissue inflammation and cytokine storm in COVID-19: lessons from SARS and MERS, and potential therapeutic interventions","volume":"257","author":"Jafarzadeh A","year":"2020","unstructured":"Jafarzadeh A, Chauhan P, Saha B, et\u00a0al. Contribution of monocytes and macrophages to the local tissue inflammation and cytokine storm in COVID-19: lessons from SARS and MERS, and potential therapeutic interventions. Life Sci. 2020;257:118102.","journal-title":"Life Sci"},{"issue":"6","key":"e_1_3_3_74_1","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1016\/j.cell.2020.08.001","article-title":"Severe COVID-19 is marked by a dysregulated myeloid cell compartment","volume":"182","author":"Schulte-Schrepping J","year":"2020","unstructured":"Schulte-Schrepping J, Reusch N, Paclik D, et\u00a0al. Severe COVID-19 is marked by a dysregulated myeloid cell compartment. Cell. 2020;182(6):1419\u20131440.e23.","journal-title":"Cell"},{"issue":"6","key":"e_1_3_3_75_1","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1038\/s41577-020-0331-4","article-title":"Pathological inflammation in patients with COVID-19: a key role for monocytes and macrophages","volume":"20","author":"Merad M","year":"2020","unstructured":"Merad M, Martin JC. Pathological inflammation in patients with COVID-19: a key role for monocytes and macrophages. Nat Rev Immunol. 2020;20(6):355\u2013362.","journal-title":"Nat Rev Immunol"},{"issue":"2","key":"e_1_3_3_76_1","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.trecan.2017.12.007","article-title":"Re-emergence of dendritic cell vaccines for cancer treatment","volume":"4","author":"Saxena M","year":"2018","unstructured":"Saxena M, Bhardwaj N. Re-emergence of dendritic cell vaccines for cancer treatment. Trends Cancer. 2018;4(2):119\u2013137.","journal-title":"Trends Cancer"},{"key":"e_1_3_3_77_1","volume-title":"Lineage cell therapeutics [Internet]","year":"2021","unstructured":"Lineage cell therapeutics [Internet]. Carlsbad (CA): lineage Cell Therapeutics, Inc; 2021 [cited 2022 Mar 11]. Available from: https:\/\/lineagecell.com\/products-pipeline\/vac2\/"},{"issue":"5","key":"e_1_3_3_78_1","first-page":"1099","article-title":"Generation of immunostimulatory dendritic cells from human CD34+ hematopoietic progenitor cells of the bone marrow and peripheral blood","volume":"55","author":"Bernhard H","year":"1995","unstructured":"Bernhard H, Disis ML, Heimfeld S, et\u00a0al. Generation of immunostimulatory dendritic cells from human CD34+ hematopoietic progenitor cells of the bone marrow and peripheral blood. Cancer Res. 1995;55(5):1099\u20131104.","journal-title":"Cancer Res"},{"issue":"10","key":"e_1_3_3_79_1","doi-asserted-by":"crossref","first-page":"2109","DOI":"10.1111\/j.1537-2995.2009.02231.x","article-title":"A simple two-step culture system for the large-scale generation of mature and functional dendritic cells from umbilical cord blood CD34+ cells","volume":"49","author":"Balan S","year":"2009","unstructured":"Balan S, Kale VP, Limaye LS. A simple two-step culture system for the large-scale generation of mature and functional dendritic cells from umbilical cord blood CD34+ cells. Transfusion. 2009;49(10):2109\u20132121.","journal-title":"Transfusion"},{"issue":"5","key":"e_1_3_3_80_1","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.3390\/ijms21051834","article-title":"Induction of antitumor immunity by exosomes isolated from cryopreserved cord blood Monocyte-Derived dendritic cells","volume":"21","author":"Than UTT","year":"2020","unstructured":"Than UTT, Le HT, Hoang DH, et\u00a0al. Induction of antitumor immunity by exosomes isolated from cryopreserved cord blood Monocyte-Derived dendritic cells. Int J Mol Sci. 2020;21(5):1834.","journal-title":"Int J Mol Sci"},{"issue":"6","key":"e_1_3_3_81_1","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1038\/ni.1615","article-title":"The receptor tyrosine kinase Flt3 is required for dendritic cell development in peripheral lymphoid tissues","volume":"9","author":"Waskow C","year":"2008","unstructured":"Waskow C, Liu K, Darrasse-J\u00e8ze G, et\u00a0al. The receptor tyrosine kinase Flt3 is required for dendritic cell development in peripheral lymphoid tissues. Nat Immunol. 2008;9(6):676\u2013683.","journal-title":"Nat Immunol"},{"issue":"4","key":"e_1_3_3_82_1","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/j.bbmt.2014.01.006","article-title":"Preactivation with IL-12, IL-15, and IL-18 induces CD25 and a functional high-affinity IL-2 receptor on human cytokine-induced memory-like natural killer cells","volume":"20","author":"Leong JW","year":"2014","unstructured":"Leong JW, Chase JM, Romee R, et\u00a0al. Preactivation with IL-12, IL-15, and IL-18 induces CD25 and a functional high-affinity IL-2 receptor on human cytokine-induced memory-like natural killer cells. Biol Blood Marrow Transplant. 2014;20(4):463\u2013473.","journal-title":"Biol Blood Marrow Transplant"},{"key":"e_1_3_3_83_1","doi-asserted-by":"crossref","first-page":"329","DOI":"10.3389\/fimmu.2017.00329","article-title":"Umbilical cord blood natural killer cells, their characteristics, and potential clinical applications","volume":"8","author":"Sarvaria A","year":"2017","unstructured":"Sarvaria A, Jawdat D, Madrigal JA, et\u00a0al. Umbilical cord blood natural killer cells, their characteristics, and potential clinical applications. Front Immunol. 2017;8:329.","journal-title":"Front Immunol"},{"issue":"1","key":"e_1_3_3_84_1","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1186\/s12896-019-0564-0","article-title":"A simple method for in\u00a0vitro preparation of natural killer cells from cord blood","volume":"19","author":"Mu YX","year":"2019","unstructured":"Mu YX, Zhao YX, Li BY, et\u00a0al. A simple method for in\u00a0vitro preparation of natural killer cells from cord blood. BMC Biotechnol. 2019;19(1):80.","journal-title":"BMC Biotechnol"},{"issue":"4","key":"e_1_3_3_85_1","doi-asserted-by":"crossref","first-page":"274","DOI":"10.5966\/sctm.2012-0084","article-title":"Clinical-scale derivation of natural killer cells from human pluripotent stem cells for cancer therapy","volume":"2","author":"Knorr DA","year":"2013","unstructured":"Knorr DA, Ni Z, Hermanson D, et\u00a0al. Clinical-scale derivation of natural killer cells from human pluripotent stem cells for cancer therapy. Stem Cells Transl Med. 2013;2(4):274\u2013283.","journal-title":"Stem Cells Transl Med"},{"issue":"1","key":"e_1_3_3_86_1","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1186\/s13287-017-0519-0","article-title":"Cytokine-free directed differentiation of human pluripotent stem cells efficiently produces hemogenic endothelium with lymphoid potential","volume":"8","author":"Galat Y","year":"2017","unstructured":"Galat Y, Dambaeva S, Elcheva I, et\u00a0al. Cytokine-free directed differentiation of human pluripotent stem cells efficiently produces hemogenic endothelium with lymphoid potential. Stem Cell Res Ther. 2017;8(1):67.","journal-title":"Stem Cell Res Ther"},{"issue":"6","key":"e_1_3_3_87_1","doi-asserted-by":"crossref","first-page":"1796","DOI":"10.1016\/j.stemcr.2017.10.020","article-title":"Generation of \"off-the-Shelf\" natural killer cells from peripheral blood cell-derived induced pluripotent stem cells","volume":"9","author":"Zeng J","year":"2017","unstructured":"Zeng J, Tang SY, Toh LL, et\u00a0al. Generation of \"off-the-Shelf\" natural killer cells from peripheral blood cell-derived induced pluripotent stem cells. Stem Cell Rep. 2017;9(6):1796\u20131812.","journal-title":"Stem Cell Rep"},{"issue":"4","key":"e_1_3_3_88_1","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1007\/s00262-015-1761-x","article-title":"NK-92: an 'off-the-shelf therapeutic\u2019 for adoptive natural killer cell-based cancer immunotherapy","volume":"65","author":"Suck G","year":"2016","unstructured":"Suck G, Odendahl M, Nowakowska P, et\u00a0al. NK-92: an 'off-the-shelf therapeutic\u2019 for adoptive natural killer cell-based cancer immunotherapy. Cancer Immunol Immunother. 2016;65(4):485\u2013492.","journal-title":"Cancer Immunol Immunother"},{"issue":"4","key":"e_1_3_3_89_1","doi-asserted-by":"crossref","first-page":"e185","DOI":"10.1111\/bjh.16895","article-title":"Harnessing HLA-E-restricted CD8 T lymphocytes for adoptive cell therapy of patients with severe COVID-19","volume":"190","author":"Caccamo N","year":"2020","unstructured":"Caccamo N, Sullivan LC, Brooks AG, et\u00a0al. Harnessing HLA-E-restricted CD8 T lymphocytes for adoptive cell therapy of patients with severe COVID-19. Br J Haematol. 2020;190(4):e185\u2013e187.","journal-title":"Br J Haematol"},{"issue":"9","key":"e_1_3_3_90_1","doi-asserted-by":"crossref","first-page":"4017","DOI":"10.4049\/jimmunol.1302259","article-title":"An overview of the intrathymic intricacies of T cell development","volume":"192","author":"Shah DK","year":"2014","unstructured":"Shah DK, Z\u00fa\u00f1iga-Pfl\u00fccker JC. An overview of the intrathymic intricacies of T cell development. J Immunol. 2014;192(9):4017\u20134023.","journal-title":"J Immunol"},{"issue":"5","key":"e_1_3_3_91_1","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1002\/embj.201387098","article-title":"iPS cells: a game changer for future medicine","volume":"33","author":"Inoue H","year":"2014","unstructured":"Inoue H, Nagata N, Kurokawa H, et\u00a0al. iPS cells: a game changer for future medicine. EMBO J. 2014;33(5):409\u2013417.","journal-title":"EMBO J"},{"issue":"1","key":"e_1_3_3_92_1","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.stem.2012.11.002","article-title":"Generation of rejuvenated antigen-specific T cells by reprogramming to pluripotency and redifferentiation","volume":"12","author":"Nishimura T","year":"2013","unstructured":"Nishimura T, Kaneko S, Kawana-Tachikawa A, et\u00a0al. Generation of rejuvenated antigen-specific T cells by reprogramming to pluripotency and redifferentiation. Cell Stem Cell. 2013;12(1):114\u2013126.","journal-title":"Cell Stem Cell"},{"issue":"9","key":"e_1_3_3_93_1","doi-asserted-by":"crossref","first-page":"2806","DOI":"10.1002\/jcb.24166","article-title":"Functional heterogeneity of mesenchymal stem cells: implications for cell therapy","volume":"113","author":"Phinney DG.","year":"2012","unstructured":"Phinney DG. Functional heterogeneity of mesenchymal stem cells: implications for cell therapy. J Cell Biochem. 2012;113(9):2806\u20132812.","journal-title":"J Cell Biochem"},{"issue":"2","key":"e_1_3_3_94_1","doi-asserted-by":"crossref","first-page":"195","DOI":"10.4252\/wjsc.v6.i2.195","article-title":"Umbilical cord-derived mesenchymal stem cells: their advantages and potential clinical utility","volume":"6","author":"Nagamura-Inoue T","year":"2014","unstructured":"Nagamura-Inoue T, He H. Umbilical cord-derived mesenchymal stem cells: their advantages and potential clinical utility. World J Stem Cells. 2014;6(2):195\u2013202.","journal-title":"World J Stem Cells"},{"issue":"6","key":"e_1_3_3_95_1","first-page":"515","article-title":"Do regenerative medicine therapies provide long-term relief in chronic low back pain: a systematic review and metaanalysis","volume":"21","author":"Sanapati J","year":"2018","unstructured":"Sanapati J, Manchikanti L, Atluri S, et\u00a0al. Do regenerative medicine therapies provide long-term relief in chronic low back pain: a systematic review and metaanalysis. Pain Physician. 2018;21(6):515\u2013540.","journal-title":"Pain Physician"},{"issue":"2","key":"e_1_3_3_96_1","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.clim.2009.09.009","article-title":"Immunologic activity and safety of autologous HIV RNA-electroporated dendritic cells in HIV-1 infected patients receiving antiretroviral therapy","volume":"134","author":"Routy JP","year":"2010","unstructured":"Routy JP, Boulassel MR, Yassine-Diab B, et\u00a0al. Immunologic activity and safety of autologous HIV RNA-electroporated dendritic cells in HIV-1 infected patients receiving antiretroviral therapy. Clin Immunol. 2010;134(2):140\u2013147.","journal-title":"Clin Immunol"},{"key":"e_1_3_3_97_1","volume-title":"SARS-CoV-2 vaccine [Internet]","year":"2020","unstructured":"SARS-CoV-2 vaccine [Internet]. Irvine (CA): AIVITA Biomedical; 2020 [cited 2022 May 2022]. Available from: https:\/\/aivitabiomedical.com\/programs\/sars-cov-2\/"},{"key":"e_1_3_3_98_1","volume-title":"ClinicalTrials.gov","author":"Aivita Biomedical, Inc.","year":"2021","unstructured":"Aivita Biomedical, Inc. Adaptive phase I clinical trial of preventive vaccine consisting of autologous dendritic cells previously incubated with S-protein from SARS-CoV-2, in subjects negative for COVID-19 infection and anti-SARS-CoV-2 antibodies. ClinicalTrials.gov [Internet]. 2021 Dec 16 [cited 2022 May 15]. Available from: https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT04690387"},{"key":"e_1_3_3_99_1","volume-title":"ClinicalTrials.gov [Internet]","author":"Aivita Biomedical, Inc","year":"2021","unstructured":"Aivita Biomedical, Inc. Adaptive phase I-II clinical trial of preventive vaccine consisting of autologous dendritic cells previously incubated with S-protein from severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), in subjects negative for COVID-19 infection and anti-SARS-CoV-2 antibodies. ClinicalTrials.gov [Internet]. 2021 Dec 16 [cited 2022 May 15]. Available from: https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT04386252"},{"key":"e_1_3_3_100_1","volume-title":"linicalTrials.gov [Internet]","author":"Shenzhen Geno-Immune Medical Institute","year":"2020","unstructured":"Shenzhen Geno-Immune Medical Institute. Phase I\/II multicenter trial of lentiviral minigene vaccine (LV-SMENP) of covid-19 coronavirus. ClinicalTrials.gov [Internet]. 2020 Mar 19 [cited 2022 May 18]. Available from: https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT04276896"},{"issue":"8","key":"e_1_3_3_101_1","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1016\/j.ymthe.2017.06.012","article-title":"Engineering natural killer cells for cancer immunotherapy","volume":"25","author":"Rezvani K","year":"2017","unstructured":"Rezvani K, Rouce R, Liu E, et\u00a0al. Engineering natural killer cells for cancer immunotherapy. Mol Ther. 2017;25(8):1769\u20131781.","journal-title":"Mol Ther"},{"issue":"6","key":"e_1_3_3_102_1","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1056\/NEJMoa1910607","article-title":"Use of CAR-transduced natural killer cells in CD19-Positive lymphoid tumors","volume":"382","author":"Liu E","year":"2020","unstructured":"Liu E, Marin D, Banerjee P, et\u00a0al. Use of CAR-transduced natural killer cells in CD19-Positive lymphoid tumors. N Engl J Med. 2020;382(6):545\u2013553.","journal-title":"N Engl J Med"},{"key":"e_1_3_3_103_1","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.coi.2018.03.013","article-title":"Next generation natural killer cells for cancer immunotherapy: the promise of genetic engineering","volume":"51","author":"Daher M","year":"2018","unstructured":"Daher M, Rezvani K. Next generation natural killer cells for cancer immunotherapy: the promise of genetic engineering. Curr Opin Immunol. 2018;51:146\u2013153.","journal-title":"Curr Opin Immunol"},{"key":"e_1_3_3_104_1","volume-title":"linicalTrials.gov [Internet]","author":"Chongqing Public Health Medical Center","year":"2020","unstructured":"Chongqing Public Health Medical Center. A phase I\/II study of universal off-the-shelf NKG2D-ACE2 CAR-NK cells secreting IL15 superagonist and GM-CSF-neutralizing scFv for therapy of COVID-19. ClinicalTrials.gov [Internet]. 2020 Nov 17 [cited 2022 May 18]. Available from: https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT04324996"},{"issue":"1","key":"e_1_3_3_105_1","doi-asserted-by":"crossref","first-page":"354","DOI":"10.4049\/jimmunol.1302999","article-title":"Proliferation conditions promote intrinsic changes in NK cells for an IL-10 response","volume":"193","author":"Tarrio ML","year":"2014","unstructured":"Tarrio ML, Lee SH, Fragoso MF, et\u00a0al. Proliferation conditions promote intrinsic changes in NK cells for an IL-10 response. J Immunol. 2014;193(1):354\u2013363.","journal-title":"J Immunol"},{"issue":"1","key":"e_1_3_3_106_1","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1186\/1465-9921-15-39","article-title":"Treatment of acute respiratory distress syndrome with allogeneic adipose-derived mesenchymal stem cells: a randomized, placebo-controlled pilot study","volume":"15","author":"Zheng G","year":"2014","unstructured":"Zheng G, Huang L, Tong H, et\u00a0al. Treatment of acute respiratory distress syndrome with allogeneic adipose-derived mesenchymal stem cells: a randomized, placebo-controlled pilot study. Respir Res. 2014;15(1):39.","journal-title":"Respir Res"},{"key":"e_1_3_3_107_1","volume-title":"linicalTrials.gov [Internet]","author":"KK Women\u2019s and Children\u2019s Hospital","year":"2020","unstructured":"KK Women\u2019s and Children\u2019s Hospital. Part two of novel adoptive cellular therapy with SARS-CoV-2 specific T cells in patients with severe COVID-19. ClinicalTrials.gov [Internet]. 2020 July 7 [cited 2022 May 19]. Available from: https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT04457726"},{"key":"e_1_3_3_108_1","volume-title":"ClinicalTrials.gov [Internet]","author":"TC Biopharm","year":"2022","unstructured":"TC Biopharm. A phase II safety and tolerability, inter-patient pre-defined dose study of ex-vivo expanded allogeneic \u03b3\u03b4 T-lymphocytes (TCB008) in patients diagnosed with COVID-19. ClinicalTrials.gov [Internet]. 2022 Mar 24 [cited 2022 May 20]. Available from: https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT04834128"},{"key":"e_1_3_3_109_1","volume-title":"clinicalTrials.gov [Internet]","author":"Mustafa Cetin, TC Erciyes University","year":"2020","unstructured":"Mustafa Cetin, TC Erciyes University. Aerosol inhalation of the exosomes derived from allogenic COVID-19 T cell in the treatment of early stage novel coronavirus pneumonia. clinicalTrials.gov [Internet]. 2020 May 15 [cited 2022 May 20]. Available from: https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT04389385"},{"issue":"31","key":"e_1_3_3_110_1","doi-asserted-by":"crossref","first-page":"e21429","DOI":"10.1097\/MD.0000000000021429","article-title":"Clinical remission of a critically ill COVID-19 patient treated by human umbilical cord mesenchymal stem cells: a case report","volume":"99","author":"Liang B","year":"2020","unstructured":"Liang B, Chen J, Li T, et\u00a0al. Clinical remission of a critically ill COVID-19 patient treated by human umbilical cord mesenchymal stem cells: a case report. Medicine. 2020;99(31):e21429.","journal-title":"Medicine"},{"issue":"1","key":"e_1_3_3_111_1","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1165\/rcmb.2019-0447TR","article-title":"Extracellular vesicles: a new frontier for research in acute respiratory distress syndrome","volume":"63","author":"Mahida RY","year":"2020","unstructured":"Mahida RY, Matsumoto S, Matthay MA. Extracellular vesicles: a new frontier for research in acute respiratory distress syndrome. Am J Respir Cell Mol Biol. 2020;63(1):15\u201324.","journal-title":"Am J Respir Cell Mol Biol"},{"issue":"12","key":"e_1_3_3_112_1","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1089\/scd.2020.0080","article-title":"Exosomes derived from bone marrow mesenchymal stem cells as treatment for severe COVID-19","volume":"29","author":"Sengupta V","year":"2020","unstructured":"Sengupta V, Sengupta S, Lazo A, et\u00a0al. Exosomes derived from bone marrow mesenchymal stem cells as treatment for severe COVID-19. Stem Cells Dev. 2020;29(12):747\u2013754.","journal-title":"Stem Cells Dev"},{"issue":"1","key":"e_1_3_3_113_1","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1007\/s12015-020-10079-6","article-title":"Nanoconjugates-based stem cell therapy for the management of COVID-19","volume":"17","author":"Desai D","year":"2021","unstructured":"Desai D, Shende P. Nanoconjugates-based stem cell therapy for the management of COVID-19. Stem Cell Rev Rep. 2021;17(1):231\u2013240.","journal-title":"Stem Cell Rev Rep"}],"container-title":["Critical Reviews in Clinical Laboratory Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/10408363.2023.2177605","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,4]],"date-time":"2023-10-04T11:34:59Z","timestamp":1696419299000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/10408363.2023.2177605"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,23]]},"references-count":112,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2023,7,4]]}},"alternative-id":["10.1080\/10408363.2023.2177605"],"URL":"https:\/\/doi.org\/10.1080\/10408363.2023.2177605","relation":{},"ISSN":["1040-8363","1549-781X"],"issn-type":[{"value":"1040-8363","type":"print"},{"value":"1549-781X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2,23]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ilab20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ilab20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2022-08-07","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-02-03","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-02-23","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}